Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Enersense to continue as Aidon’s partner in Helen’s district heating metering agreement

Enersense International PlcPress release, 4 January 2024 at 10:50 a.m.The Smart Industry business area of Enersense, a provider of zero-emission energy solutions, and Aidon have agreed to continue their cooperation in the implementation of the agreement on the provision of measurement and remote reading services for Helen’s district heating and cooling. The new five-year agreement period will enter into force on 1 January 2024. Enersense is responsible for the installation, service, repair and maintenance of Helen’s measuring equipment covered by the agreement in the field. The

BioStock: Chordate continues its marketing activities and exit strategy

In 2023, Chordate Medical has taken steps forward in the commercial progress with the migraine treatment Ozilia. The long-term goal is to sell the company. To continue working towards this goal, the company intends to carry out a rights issue of 41.8 MSEK. BioStock reached out to CEO Anders Weilandt to find out more.Read the full article at biostock.se : https://www.biostock.se/en/2024/01/chordate-continues-its-marketing-activities-and-exit-strategy/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 4 - 4 JANUARY 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 186/23 and 187/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

Metsä Board showcases its carbon-reducing concept for premium gift packaging at the Paris Packaging Week

Metsä Board Corporation press release 4.1.2024Metsä Board, part of Metsä Group, will be exhibiting its future-ready premium paperboards, innovative new packaging solutions and services for co-creation to the beauty industry at the 2024 Paris Packaging Week in January. During January 17 – 18, the PCD event will gather packaging developers, designers and suppliers shaping future of packaging for the beauty market to the Paris Expo Porte de Versailles exhibition centre. At Metsä Board’s booth (L60), visitors will have the opportunity to challenge a team of experts with their specific

Diamyd® precision medicine Phase 3 trial key interim analysis in July

The upcoming interim analysis of the transformational gene-based precision medicine Phase 3 trial, DIAGNODE-3, for type 1 diabetes is planned for July 2024. This precision medicine trial employs the antigen-specific immunotherapy Diamyd[®] and the interim assessment, focusing on the preservation of endogenous insulin production as measured by C-peptide levels at 6 months follow-up, will include data from 70-80 patients presently enrolled in DIAGNODE-3. This analysis is an important milestone, providing insights into the trial's progress towards achieving its primary goals.DIAGNODE-3, the

Assemblin Electrical strengthens service operations in Västra Götaland (Sweden) through acquisition

Assemblin Electrical has acquired the service company Elservice Västra Götaland AB ("Elservice") with operations in Lidköping, an annual turnover of approximately SEK 30 million and 14 employees.Elservice was founded in 2014 and is today a stable electrical service company with headquarter in Lidköping and operations in Västra Götaland (Sweden). Elservice offers electrical service and installation projects. The customer base mostly consists of construction companies, property owners and private individuals. The company mainly performs work in connection with renovations and new

Fortum’s Loviisa nuclear power plant generated 8.09 terawatt-hours of carbon-free electricity in 2023

FORTUM CORPORATION PRESS RELEASE 4.1.2024 Fortum’s Loviisa nuclear power plant had a good production year in 2023. The power plant generated a total of 8.09 terawatt-hours of carbon-free electricity.  Loviisa 1 generated 3.99 TWh of power and its load factor was 89.79%; Loviisa 2 generated 4.10 TWh of power and its load factor was 92.32%. The combined load factor of the plant units was 91.06%. “Last year Loviisa produced about 10% of Finland’s electricity demand. This is equivalent to the electricity consumption of the entire Helsinki metropolitan area,” says Sasu Valkamo, Vice

Announcement of a change in shareholding according to Chapter 9, Section 10 of the Finnish Securities Market Act

Announcement of a change in shareholding according to Chapter 9, Section 10 of the Finnish Securities Market Act Musti Group plc                         Stock Exchange Release                                         4 January 2024 at 9.45am Musti Group plc (the “Company”) has on 3 January 2024 received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act from The Goldman Sachs Group, Inc. (”GS”), according to which GS’s holding of the shares and votes of the Company increased above the threshold of 5 percent on 2 January 2024. GS holds a

Nitro Games expects revenue increase and a positive result for Q4 / 2023

As a result of continued revenue increase and careful cost control, the company expects a profitable fourth quarter of 2023, with a positive cash flow. Nitro Games Oyj’s key figures in the fourth quarter of 2023 according to preliminary and unaudited calculations are the following (comparison figures from the previous year in parenthesis): Q4/2023 · Revenues increased to approximately EUR 2.9 million (EUR 2.3 million) · EBITDA increased to approximately EUR 0.7 million (EUR -0.4 million) · EBIT increased to approximately EUR 0.3 million (EUR -0.6 million) · Net result

Nordnet: Monthly statistics December

In December, Nordnet’s customers made 3,832,700 trades in listed financial instruments, which corresponds to 203,900 trades per day. The number of new customers in December amounted to 12,900 and the number of new customers in 2023 is 155,000. The total number of customers at the end of December was 1,862,900. Net savings for December was SEK 3.5 billion and the total net savings during 2023 is SEK 34.7 billion. The savings capital was SEK 825 billion and lending amounted to SEK 29.5 billion at the end of December. +-----------------+---------+---------+---------+---------+--------+|

Alex Therapeutics Reports Positive Results from the Randomized-Controlled Trial of its Digital Therapy for Anxiety

●        AlmeeTM, developed by Alex Therapeutics in partnership with Vicore Pharma, is a mobile app that offers personalized treatment for anxiety based on cognitive behavioral therapy (CBT) ●        The pivotal trial demonstrated significantly reduced levels of anxiety and improved quality of life for people living with pulmonary fibrosis, a chronic and fatal disease   Stockholm, January 4, 2024 – Alex Therapeutics and Vicore Pharma today announced positive results of the COMPANION study, investigating the efficacy of Almee, a 9-week digital cognitive behavioral therapy (CBT)

Repurchase of Outokumpu’s own shares

Outokumpu OyjStock exchange releaseJanuary 4, 2024 at 9.30 am EETRepurchase of Outokumpu’s own shares On January 3, 2024, Outokumpu has completed repurchases of its own shares as follows (ISIN FI0009002422): +-------+----------------+------------------------------------+----------------+|Trading|Number of shares|Weighted average price / share, EUR*|Total cost, EUR*||venue | | | |+-------+----------------+------------------------------------+----------------+|CEUX |111,303 |4.2089

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir’s licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has dosed the first patient with TNG348, a novel USP1 inhibitor. Tango received U.S. Food and Drug Administration clearance on its Investigational New Drug application for TNG348 in September 2023.   TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor for the treatment of BRCA1/2-mutant and other homologous

TF Bank AB (publ): Invitation to the presentation of the Year-end report 2023

TF Bank AB will publish its Year-end report for 2023 on Friday 19 January 2024 at 07.00 CET. We welcome media, institutional investors, analysts and other interested parties to participate in a conference call at 08.15 CET.  Agenda (CET)  07.00 – Year-end report published  08.15 – Conference call with CEO Joakim Jansson and CFO Mikael Meomuttel who will present the Year-end report. It will be possible to ask questions after the presentation.  To follow the conference call online go to www.tfbankgroup.com. To participate in the conference call, please click on the Zoom link below

NYAB Oyj - Managers' Transactions

NYAB PlcMANAGERS' TRANSACTIONS04 January 2024 at 09:30NYAB Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: PM Ruukki OyPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Markku KankaalaPosition: Member of the BoardIssuer: NYAB OyjLEI: 743700UX7WTIOT3QO547Notification type: INITIAL NOTIFICATIONReference number: 48545/5/5 ____________________________________________Transaction date: 2023-12-27Outside a trading venue

Agreement with the IT distributor N.O.D is increased by 75 million DKK

Company Announcement no. 1-24Copenhagen, January 4, 2024 In reference to company announcement no. 28-23, Shape Robotics and Network One Distribution are extending the framework agreement by an additional minimum of €10 million (approx. MDKK 75) to be delivered in 2024. The framework agreement encompasses a broad spectrum of Shape Robotics solutions, including proprietary products and third-party offerings, primarily for public acquisitions in Component C 15: Education of PNRR, which includes "SmartLabs. Today's news does not alter the guidance announced for 2024, where Shape

Metso to deliver four FIT Crushing Stations in the Americas

Metso Corporation’s press release on January 4, 2024, at 09:00 a.m. EETMetso will supply four FIT™ Crushing Stations in the Americas. Three of the crushing stations will be delivered to an iron ore mine in Brazil and one to a gold plant in Canada. The combined value of the orders is approximately EUR 20 million. The Brazilian orders are booked in Metso’s Minerals segment 2023 fourth-quarter order intake.  The game-changing crushing and screening solution was launched in 2020. Since then, Metso has sold 24 FIT™ Stations around the world for applications ranging from gold, iron ore,

Transaction in Own Shares

    04 January 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |03/01/2024|+-----------------------------------------------------------

Cereno Scientific submits request to the FDA for “compassionate use” of CS1 for treatment of patients with rare disease Pulmonary Arterial Hypertension (PAH)

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the company has submitted a request to the FDA for Expanded Access, sometimes called “compassionate use”, to investigational drug CS1 for use in an extension of the ongoing Phase II trial evaluating CS1 in PAH. The initiative is prompted by a request from an investigator in the ongoing Phase II study. Cereno has submitted a request to the FDA under the ‘Expanded Access to Investigational Drugs for Treatment Use’ for expanded access to CS1,

Paul Smith signs with Ingrid

Paul Smith, Britain’s leading independent design company, partners with the delivery experience platform Ingrid to optimize their global delivery operations and cover all stages of the customer journey with a strong personal touch. Founded as a small shop in Nottingham in 1970, Paul Smith has grown into a global brand sold on six continents. It has flourished from menswear design into a lifestyle company for everyone, known for its distinctive signature multi-coloured stripes. “You can find inspiration in everything,” Sir Paul Smith says. Paul Smith clothes are

UNION therapeutics announces enrollment of the first patient in the UCORIS Phase 2 IIT study of orismilast in patients with ulcerative colitis

· UCORIS is an investigator-initiated, Phase 2 study of orismilast for the treatment of moderate to severe ulcerative colitis (UC) · UC is a chronic, inflammatory bowel disease with substantial unmet medical need for new oral treatments · Orismilast is a next-generation, high potency PDE4 B/D selective inhibitor with recently reported positive Phase 2b results in psoriasis and Phase 2 results in hidradenitis suppurativa (HS); orismilast also recently completed enrollment in an ongoing Phase 2b study in atopic dermatitis   Hellerup, Denmark, January 4, 2024 – UNION therapeutics A/

Invitation to presentation of EQT AB’s Year-end Report 2023

EQT AB’s Year-end Report 2023 will be published on Thursday 18 January 2024 at approximately 07:00 CET. EQT will host a conference call at 08:30 CET to present the report, followed by a Q&A session.The presentation and a video link for the webcast will be available here  from the time of the publication of the Year-end Report. To participate by phone and ask questions during the Q&A, please register here  in advance. Upon registration, you will receive your personal dial-in

More lives can be saved if ambulance staff receive AI-support

Assessing how seriously injured a person is, involves weighing up lots of different parameters fast. If healthcare professionals could get support making fast-paced, life-critical decisions from an AI tool, more lives could be saved. This is shown by research from Chalmers University of Technology in Sweden, along with the University of Gothenburg and the University of Borås. "If severely injured people are transported directly to a university hospital, the chances of survival increase, as there are resources to take care of all types of injuries. Therefore, we need to be able

Salmon Evolution ASA: Q4 2023 Operational update

Salmon Evolution ASA ("Salmon Evolution" or the "Company", OSE: SALME) ends 2023 with an all-time high biomass and record harvest volumes in Q4. As per 31 December 2023 the Company had a standing biomass of more than 2,200 tonnes (LW) and had all-time high net biomass production of 1,439 tonnes (LW) in the quarter. The Company continues to see strong biological performance with good appetite and low mortality at Indre Harøy. Salmon Evolution harvested a record high 1,104  tonnes (HOG) in the fourth quarter, with a 90 % superior share and tight weight concentration. Harvest volumes in

There are no items matching the current filter
There are no more items matching the current filter
Back to top